PD17-02 COST IMPLICATIONS OF INFECTIOUS COMPLICATIONS FOLLOWING PROSTATE BIOPSIES IN THE UNITED STATES

Abstract

You have accessJournal of UrologyCME1 May 2022PD17-02 COST IMPLICATIONS OF INFECTIOUS COMPLICATIONS FOLLOWING PROSTATE BIOPSIES IN THE UNITED STATES Sharon White, Eric Ballon-Landa, Michael Bronsert, Boris Gershman, Peter Clark, Granville Lloyd, Jeffrey Morrison, Rodrigo Rodrigues-Pessoa, Marc Smaldone, Anessa Sax-Bolder, and Simon Kim Sharon WhiteSharon White More articles by this author , Eric Ballon-LandaEric Ballon-Landa More articles by this author , Michael BronsertMichael Bronsert More articles by this author , Boris GershmanBoris Gershman More articles by this author , Peter ClarkPeter Clark More articles by this author , Granville LloydGranville Lloyd More articles by this author , Jeffrey MorrisonJeffrey Morrison More articles by this author , Rodrigo Rodrigues-PessoaRodrigo Rodrigues-Pessoa More articles by this author , Marc SmaldoneMarc Smaldone More articles by this author , Anessa Sax-BolderAnessa Sax-Bolder More articles by this author , and Simon KimSimon Kim More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002555.02AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Infectious complications following transrectal ultrasound prostate biopsies (TRUS-PB) represent a growing burden in the U.S. Understanding the health care costs attributable to these adverse outcomes following this common urologic procedure is essential but remains largely unknown. Herein, we describe the economic burden attributable to post TRUS-PB infectious complications from a population-based cohort of privately-insured patients. METHODS: From 2010 to 2015, we identified all patients who underwent an incident TRUS PB from MarketScan. Health care costs and patient out-of-pocket costs due to infectious complications requiring hospital admission and emergency room (ER) visits within 30 days of the TRUS-PB represented the primary outcome. Multivariable analyses were used to identify patient characteristics associated with higher health care and out-of-pocket costs. RESULTS: Overall, 193,490 patients underwent TRUS-PB and the mean age was 57.6 years (SD: 5.0). The rates of infectious complications requiring ER visits and hospital admissions were 0.4 and 1.2 per 100 prostate biopsies. Compared to patients who did not experience any infectious complications, patient admitted to hospital within 30 days had higher health care costs ($14,057 vs. $625; p < 0.001) and out-of-pocket costs ($80 vs. $9; p<.0001). Similarly, patients who required ER visits also had higher total health care costs compared to those who did not experience infectious complications ($141 vs. $4; p<.0001). Higher aggregate health care costs ($14,198 vs. $629; p<.0001) and out-of-pockets costs ($89 vs. $18; p<.0001) were observed for patients who sustained infectious complications. The total health care cost for infections was $38,234,689 On multivariable analyses, patients who had Elixhauser index defined comorbidities had total health care costs (p<0.001). CONCLUSIONS: Infectious complications following TRUS-PB are associated with significant economic burden to the health care system and patients. Efforts to reduce post TRUS-PB infectious complications can significantly improve value-based health care delivery. Source of Funding: This study was supported by the Schramm Foundation © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e336 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Sharon White More articles by this author Eric Ballon-Landa More articles by this author Michael Bronsert More articles by this author Boris Gershman More articles by this author Peter Clark More articles by this author Granville Lloyd More articles by this author Jeffrey Morrison More articles by this author Rodrigo Rodrigues-Pessoa More articles by this author Marc Smaldone More articles by this author Anessa Sax-Bolder More articles by this author Simon Kim More articles by this author Expand All Advertisement PDF DownloadLoading ...